On July 31, Meda announced the acquisition of Italian Rottapharm. With the acquisition, Meda becomes a leading European specialty pharma company with pro forma revenues of more than 18 billion in 2013. The combined entity will have enhanced scale, broader geographical presence and dispose of a product portfolio that is well balanced between Rx and Cx / OTC. Cost synergies for the combined entity is estimated to SEK 900 million, with full effect in 2016.
Below aggregated, published information about the whole acquisition – links.